The Development of a Novel Nanobody Therapeutic for SARS-CoV-2 is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2020). On theSindex it has a DataRank of 0.489. It has been cited 25 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.489
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 2R35GM118047-06
Structural studies of viral replication and invasion
National Science Foundation
Grant: 2029943
RAPID Enhanced SARS-CoV-2 High-Throughput Crystallization for Structural Studies
National Institutes of Health
Grant: 7R01AI157975-02
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses
National Institutes of Health
Grant: 5R01AI089728-07
Receptor recognition and cell entry of coronaviruses
NIAID NIH HHS
Grant: R01 AI089728
NIAID NIH HHS
Grant: R01 AI157975
NIGMS NIH HHS
Grant: R35 GM118047
Fields of Study
Keywords
Sustainable Development Goals